Ceritinib
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 766 publications
Expert consensus on iruplinalkib for the treatment of ALK-positive non-small cell lung cancer (2026 edition)
Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]
Published: July 25, 2026
Longitudinal Treatment Outcomes in Patients With Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer: Results From a Multinational Registry-Based Study in a Predominantly Western Population.
Journal: JCO global oncology
Published: June 24, 2026
Rescuing a refractory Leiomyosarcoma: ALK-DCTN1 fusion as a gateway to long-term control with Ceritinib.
Journal: Gynecologic oncology reports
Published: June 01, 2026
First-Line Alectinib Versus Ceritinib With or Without Brain Radiotherapy in ALK-Positive Non-Small Cell Lung Cancer with Brain Metastases: A Real-World Multicenter Study from Vietnam.
Journal: Thoracic cancer
Published: May 13, 2026
Identification of Der p1 inhibitors: Combining AI-based QSAR, molecular docking, molecular dynamics simulations and quantum physics.
Journal: Computational biology and chemistry
Published: May 11, 2026
A hydrogen sulfide activated fluorescence probe for screening tumor cells and diagnosis of non-small cell lung carcinoma.
Journal: Journal of photochemistry and photobiology. B, Biology
Published: May 11, 2026
Clinical Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitors for the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer Based on the 2nd Edition of China's Drug Evaluation and Selection Guideline.
Journal: Drug design, development and therapy
Published: May 10, 2026
Small Cell Transformation of Metachronous ALK + ve Lung and Prostatic Adenocarcinoma following Initial Response to Ceritinib and Androgen Deprivation Therapies and Metastases to Two Different Organs: Guidance through FDG-PET/CT and 68 Ga-PSMA-11 PET-CT and Biopsy-Immunohistochemistry Correlation.
Journal: World journal of nuclear medicine
Published: May 04, 2026
Lorlatinib in patients with ALK-positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV study.
Journal: Future oncology (London, England)
Published: April 08, 2026
Last Updated: 09/26/2026